

PENVARD  
(Vardhman Exports),

## **SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE MEDICINAL PRODUCT

PENICILLIN V. POTASSIUM TABLETS USP 5, 00,000IU

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each uncoated tablet contains:

Penicillin V Potassium USP eq. to

Penicillin V 5, 00,000IU (EQ 312.5mg)

Excipients with known effects:

Each tablet contains 50.00 mg of Lactose, 6.50 mg of Magnesium Stearate.

For full list of excipients, see section 6.1

## 3. PHARMACEUTICAL FORM

White circular uncoated tablets having 'PENICILLIN V' embossed on one side and '500000 IU' with breakline on other side of each tablet.

The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

For use in the treatment of mild to moderately severe infections caused by penicillin sensitive organisms.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

### 4.2 Posology and method of administration

#### Posology

**Adults:** The dosage is 250-500 mg every six hours.

**Elderly:** The dosage is as for adults. The dosage should be reduced if renal function is markedly impaired.

**Prophylactic Use:** The dosage is 250 mg daily for long term prophylaxis of rheumatic fever.

#### **Paediatric population**

**Children** 1-5 years: 125 mg every six hours

6-12 years: 250 mg every six hours

To avoid late complications (rheumatic fever), infections with  $\beta$ -haemolytic streptococci should be treated for 10 days.

The treatment of acute otitis media with Penicillin V Potassium should be limited to 5 days. However, 5-10 days treatment may be recommended in patients with potential for complications.

### **Method of administration**

Penicillin V Potassium Tablets are for oral use.

Each tablet should be swallowed whole with water, at least 30 minutes before food, as ingestion of Penicillin V Potassium with meals slightly reduces the absorption of the drug.

### **4.3 Contraindications**

Penicillin V Potassium is contraindicated in patients with known penicillin hypersensitivity.

Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics e.g. cephalosporins. Severe acute infections should not be treated with Penicillin V Potassium.

### **4.4 Special warnings and precautions for use**

Penicillin V Potassium should be given with caution to patients with a history of allergy, especially to other drugs. Penicillin V Potassium should also be given cautiously to cephalosporin-sensitive patients, as there is some evidence of partial cross-allergenicity between the cephalosporins and penicillins. Patients have had severe reactions (including anaphylaxis) to both drugs. If the patient experiences an allergic reaction Penicillin V Potassium should be discontinued and treatment with the appropriate agents initiated (e.g. adrenaline and other pressor amines, antihistamines and other corticosteroids).

Particular caution should be exercised in prescribing Penicillin V Potassium to patients with an allergic diathesis or with bronchial asthma

Oral penicillins are not indicated in patients with severe illness or with a gastrointestinal disease that causes persistent nausea, vomiting gastric dilation, cardiospasm, intestinal hypermotility or diarrhoea because absorption may be reduced. Occasionally, patients do not absorb therapeutic amounts of orally administered penicillin.

Streptococcal infections should be treated for a minimum of 10 days and post-therapy cultures should be performed to confirm the eradication of the organisms.

In patients undergoing long-term Penicillin V Potassium treatment the complete and differential blood count, as well as the liver and kidney function, should be monitored.

During long-term treatment attention should also be paid to the potential overgrowth of resistant organisms including *Pseudomonas* or *Candida*. If super-infection occurs, appropriate measures should be taken.

Caution should be used when treating patients with a history of antibiotic-associated colitis.

Each tablet of Penicillin V Potassium tablets may be harmful to people on low potassium diets and may cause stomach upset, diarrhoea and hyperkalaemia. High doses should be used with caution in patients receiving potassium-containing drugs or potassium sparing-diuretics.

In renal impairment the safe dosage may be lower than usually recommended.

During treatment with Penicillin V Potassium non-enzymatic glucose tests may be false-positive.

### **4.5 Interaction with other medicinal products and other forms of interaction**

As penicillins like Penicillin V Potassium are only active against proliferating microorganisms, Penicillin V Potassium should not be combined with bacteriostatic antibiotics such as tetracycline, erythromycin, chloramphenicol and sulphonamides.

Concomitant use of uricosuric drugs (e.g. probenecid and sulfapyrazone) reduces the excretion of Penicillin V Potassium resulting in increased plasma levels and thus prolongs its action.

Penicillin V Potassium may reduce the excretion of methotrexate causing an increased risk of toxicity.

During treatment with Penicillin V Potassium non-enzymatic urinary glucose tests may be false-positive.

Guar gum may slow the speed of absorption of Penicillin V Potassium.

Penicillin V Potassium has the following interaction information:

Neomycin - absorption of Penicillin V Potassium reduced by neomycin.

Combined use of Penicillin V Potassium and oral anticoagulants (e.g. warfarin) may prolong prothrombin time.

Coumarin – common experience in anticoagulant clinics is that INR can be altered by a course of broad-spectrum penicillins such as ampicillin, although studies have failed to demonstrate an interaction with coumarins.

Phenindione – common experience in anticoagulant clinics is that INR can be altered by a course of broad-spectrum penicillins such as ampicillin, although studies have failed to demonstrate an interaction with phenindione.

Thyphoid Vaccines – antibacterials inactive oral typhoid vaccine.

#### **4.6. Fertility, Pregnancy and lactation**

##### **Pregnancy**

Animal studies with Penicillin V Potassium have shown no teratogenic effects.

Penicillin V Potassium has been in extensive clinical use and suitability in human pregnancy has been well documented in clinical trials. However, as with other drugs, caution should be exercised when prescribing to pregnant patients.

##### **Lactation**

Breast feeding is not contraindicated with Penicillin V Potassium. Trace quantities of Penicillin V Potassium can be detected in breast milk. While adverse effects are apparently rare, two potential problems exist for nursing infant:

- modification of bowel flora
- direct effects on the infant such as allergy/sensitisation

Caution should therefore be exercised when prescribing for the nursing mother.

#### **4.7 Effects on ability to drive and use machines**

None known.

#### **4.8 Undesirable effects**

##### **Hypersensitivity**

Potential allergic reactions include urticaria, angioneurotic oedema, erythema multiforme, exfoliative dermatitis, fever, joint pain, serum sickness-like reactions, haemolytic anaemia, interstitial nephritis or anaphylactic shock (which could be fatal) with collapse and anaphylactoid reactions (asthma, purpura, gastrointestinal symptoms). Although these are less common, and take a milder course, in oral treatment than during parenteral penicillin treatment, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been observed with oral penicillin.

##### **Gastro-intestinal tract**

Penicillin V Potassium is generally well tolerated. Occasionally soft stools occur and they do not require the interruption of the treatment.

Nausea, diarrhoea, vomiting, stomatitis and glossitis are sometimes seen.

Sustained severe diarrhoea should prompt suspicion of pseudomembranous colitis. As this condition may be life-threatening Penicillin V Potassium should be withdrawn immediately and treatment guided by bacteriologic studies with appropriate antibiotherapy (i.e. vancomycin)..

#### Blood

Eosinophilia, haemolytic anaemia, leukopenia, thrombocytopenia and agranulocytosis are extremely rare. Other possible effects on the blood composition include: neutropenia, haemolytic anaemia and coagulation disorders.

#### Central nervous system

Central nervous system toxicity, including convulsions, has been reported, especially following high doses or in severe renal impairment. Paraesthesia has been reported with prolonged use.

As with other broad-spectrum antibiotics prolonged use may result in the overgrowth of non-susceptible organisms, e.g. candida. This may present a vulvo-vaginitis.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

### **4.9 Overdose**

A large overdose may cause nausea, vomiting and diarrhoea. Rarely major motor seizures may occur. There is no known antidote. Symptomatic and supportive therapy is recommended. It is advisable to monitor blood levels in patients with renal malfunction. Penicillin V Potassium may be removed by haemodialysis.

## **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antibacterial agents.

ATC code: J01 CE 02

#### Mechanism of action

Penicillin V Potassium is a broad spectrum beta-lactam antibiotic with bactericidal action against Gram-positive bacteria and Gram-negative cocci. Its antimicrobial action is similar to that of benzyl penicillin. Penicillin V Potassium is usually active against the following organisms:

Gram-positive aerobes and anaerobes including

Bacillus anthracis

Clostridium perfringens

Clostridium tetani

Corynebacterium diphtheriae

Erysipelothrix rhusiopathiae

Listeria monocytogenes

Peptostreptococcus spp.

Streptococcus agalactiae (Group B)

Streptococcus pneumoniae

Streptococcus pyogenes (Group A)

Gram-negative including

Neisseria meningitidis

Neisseria gonorrhoeae

Penicillin V Potassium is inactivated by penicillinase and other beta-lactamases.

Penicillin V Potassium binds to penicillin-binding proteins located on the inner membrane of the bacterial cell wall. Penicillin V Potassium binds to and inactivates these proteins resulting in weakening of the bacterial cell wall and lysis.

## **5.2 Pharmacokinetic properties**

### Absorption

Penicillin V Potassium is stable under acidic conditions so it can be administered by oral route.

Penicillin V Potassium is rapidly, but incompletely absorbed after oral administration and the absorption level is around 60%. The simultaneous administration of food slightly decreases the peak plasma concentration of Penicillin V Potassium, but does not appear to affect the extent of absorption. Peak plasma concentrations are reached in about 45 minutes. The peak plasma concentration increases approximately in proportion with increased doses. Peak serum concentrations of 3-6 jig per ml have been seen following dosage of 250 mg to 500 mg by mouth.

### Distribution

Penicillin V Potassium is widely distributed round the body tissues and fluids (volume of distribution about 0.2 l kg<sup>-1</sup> of body weight) and more readily penetrates inflamed tissues. It also diffuses across the placenta into foetal circulation and small amounts appear in the milk of nursing mothers. Eighty per cent is reported to be protein bound.

### Biotransformation

Penicillin V Potassium is partially metabolised to inactive penicilloic acid by hydrolysis of the lactam ring. This metabolism occurs in the liver.

### Elimination

The plasma half-life of Penicillin V Potassium is about 45 minutes which may increase to four hours in renal failure.

Excretion is by tubular secretion into urine. About 40% of the dose is eliminated in the urine either as unchanged or as penicilloic acid in the first 10 hours after oral administration. Small excretion occurs in bile.

Impaired absorption is seen in patients with coeliac disease.

## **5.3 Preclinical safety data**

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of this SPC.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Lactose,  
Maize Starch,  
PVPK-30,  
Purified Talc,  
Colloidal Silicon Dioxide,  
Sodium Starch Glycollate,  
Magnesium Stearate.

## **6.2 Incompatibilities**

Not applicable.

## **6.3 Shelf life**

3 years

## **6.4 Special precautions for storage**

Store in a cool place and dry place .Protect from light. Keep all medicines out of reach of children.

## **6.5 Nature and contents of container**

10 tablets are packed in a plastic transparent container and such container labelled with product label and packed in printed inner carton with a literature.

## **6.6 Special precautions for disposal and other handling**

No special requirements.

## **7. APPLICANT/MANUFACTURER**

### **NAME & ADDRESS:**

### **VARDHMAN EXPORTS**

A – 188, TTC, MIDC Industrial Area,  
Khairane, Navi Mumbai 400 710.

**INDIA.**

TEL. / FAX : 91 22 4102 6622